Skip to main content
. 2016 Apr 26;7(23):34860–34880. doi: 10.18632/oncotarget.8992

Figure 7. Trk inhibition enhances the antiproliferative effects of VCR, VP-16 and doxorubicin synergistically in chemoresistant ES cells.

Figure 7

A-C. Cells were treated and analyzed as in Figure 6. All adjuvant treatments produced significant reduction in cell proliferation compared to non-treated controls; some differed significant from single treatments. * vs. control; # vs. respective K252a dose; & vs. respective chemotherapeutic dose. Single, double, and triple symbols represent p < .05, p < .01, p < .001, respectively. See Table 3 for additional related data. SK-ES-1R treated with VCR (n = 4), VP-16 (n = 3), Doxo (n = 3), where n is number of independent experiments contributing to mean data shown. Doxo = doxorubicin; VCR = vincristine; VP-16 = etoposide.